200 likes | 213 Views
Discover the thoughts and actions of executives in life sciences and medtech regarding Brexit, highlighting challenges and opportunities. Peer opinions shed light on the complexity, workforce concerns, funding issues, and regulatory changes post-Brexit. Gain valuable insights to navigate the industry landscape confidently.
E N D
BREXIT: WHAT IS ON THE MINDS OF EXECUTIVES IN LIFE SCIENCES AND MEDTECH 9 OCTOBER 2017
OVERVIEW Find out what are people in the life sciences and medtech are thinking and doing about BREXIT The highlights: 60% could not see any opportunity at all coming from BREXIT Regulatory, Attracting/Retaining/Developing staff, and funding from government sources the top 3 challenges Opinions from the peer group reveal further insights: It’s complex The UK is less attractive for skilled scientists, concern is they’re leaving The loss of European funding is impacting R&D plans There are some positives, e.g. choosing GDPR alleviates different national data protection laws The data follows, and the peer group opinions will provide valuable insights that we hope helps you and the industry.
Opportunities HOW DID WE DO IT? Challenges Brexit You’re right, it’s a focused survey Opinions Demographics
What do you see as the biggest three opportunitiesof BREXIT for your business in life sciences/healthcare? OPPORTUNITIES You told us… …and you also added…
What do you see as the biggest three challenges of BREXIT for your business in life sciences/healthcare? CHALLENGES You told us… …and you also added…
Please add a comment or sharing with your peers YOUR VIEWS TO SHARE You shared…
YOU SHARED… Answered: 39 Skipped: 20
YOU SHARED… Answered: 39 Skipped: 20
YOU SHARED… Answered: 39 Skipped: 20
YOU SHARED… Answered: 39 Skipped: 20
YOU SHARED… Answered: 39 Skipped: 20
THANK YOU FOR YOUR CONTRIBUTION SHAPING THE LEADERSHIP THAT IS SHAPING TOMORROW +44 (0)20 7487 0078 (tel) +44 (0)870 486 2038 (fax) mail@aggiosergeant.com aggiosergeant.com 46 MANCHESTER STREET LONDON W1U 7LS UNITED KINGDOM